

SUPPLEMENTARY MATERIAL

Synthetic Studies Toward Diazonamide A. A Novel Approach for Polyoxazole Synthesis

Peter Wipf* and Joey-Lee Methot

*Department of Chemistry, University of Pittsburgh, Pittsburgh,
Pennsylvania 15260, U.S.A.*

Experimental parts. ^1H and ^{13}C NMR spectra.

General: All reactions were performed in flame-dried or oven-dried glassware under a dry nitrogen atmosphere. THF and ether were distilled over Na/benzophenone, while toluene, CH₂CH₂, and *i*-Pr₂NH were distilled over CaH₂. Hexanes and EtOAc were distilled prior to use. All other reagents and solvents were used as received unless otherwise noted. NMR spectra were recorded in CDCl₃ (unless otherwise noted) at either 300 MHz (¹H NMR) or 75 MHz (¹³C NMR) using Bruker Avance 300 with XWIN-NMR software. IR spectra were obtained neat unless otherwise noted.

(5-Phenyl-oxazol-2-ylmethyl)-carbamic acid benzyl ester (12). A suspension of Cbz-Gly¹ (5.01 g, 24.0 mmol) in 100 mL of CH₂Cl₂ was treated with *i*-Pr₂NEt (12.5 mL, 71.8 mmol) and cooled to -20 °C. Diethyl cyanophosphonate (5.00 mL, 33.0 mmol) was added and the mixture was stirred for 30 min. After the addition of a solution of α-aminoacetophenone hydrochloride (3.75 g, 21.8 mmol) in 20 mL of CH₂Cl₂, the reaction mixture was stirred for 2 h at -20 °C, and for 14 h at room temperature. The solution was diluted with CH₂Cl₂, washed with 10% HCl and saturated NaHCO₃, dried (MgSO₄), filtered and concentrated. Chromatography on SiO₂ (EtOAc/hexanes, 1:1) provided 6.19 g (87%) of the desired ketoamide as a foam: ¹H NMR (DMSO-*d*₆) δ 8.20 (t, 1 H, *J* = 5.2 Hz), 7.99 (d, 2 H, *J* = 7.6 Hz), 7.67 (t, 1 H, *J* = 7.3 Hz), 7.57-7.52 (m, 3 H), 7.37-7.30 (m, 5 H), 5.04 (s, 2 H), 4.64 (d, 2 H, *J* = 5.4 Hz), 3.72 (d, 2 H, *J* = 6.2 Hz).

A solution of this ketoamide (6.19 g, 19.0 mmol) in 200 mL of CH₂Cl₂ was treated with PPh₃ (10.0 g, 3.81 mmol) and NEt₃ (10.6 mL, 7.61 mmol). At 0 °C, a solution of Cl₃CCCl₃ (9.00 g, 3.80 mmol) in 50 mL of CH₂Cl₂ was added dropwise. The reaction mixture was stirred for 1 h, then warmed to room temperature and stirred for another 1 h. The black solution was washed with 10% HCl and saturated NaHCO₃, dried (MgSO₄), filtered, and concentrated. Chromatography on SiO₂ (EtOAc/hexanes, 1:4) provided 3.31 g (56%) of oily oxazole **12**: *R*_f 0.50 (EtOAc/hexanes, 1:1); IR 1724 cm⁻¹; ¹H NMR δ 7.59 (d, 2 H, *J* = 7.4 Hz), 7.5-7.3 (m, 9 H), 7.24 (s, 1 H), 5.85 (br m, 1 H), 5.17 (s, 2 H), 4.58 (d, 2 H, *J* = 5.8 Hz); ¹³C NMR δ 160.5, 156.5, 152.1, 136.4, 129.1, 128.7, 128.4, 127.8, 124.4, 122.0, 67.4, 38.7; MS (EI) *m/z* (rel. intensity) 308 (M⁺, 13), 217 (15), 203 (7), 173 (95), 91 (100); HRMS (EI) *m/z* calculated for C₁₈H₁₆N₂O₃ 308.1161, found 308.1147.

¹ Hayashi, T.; Asai, T.; Ogoshi, H. *Tetrahedron Lett.* **1997**, 38, 3039-3042.

(2,2-Dimethyl-propionyl)-(5-phenyl-oxazol-2-ylmethyl)-carbamic *tert*-butyl ester (13). A solution of oxazole **12** (854 mg, 2.77 mmol) in 20 mL of EtOH was treated with 10% Pd/C (150 mg, ca. 0.05 eq). After repeated degassing under vacuum/H₂, the suspension was stirred vigorously for 2 h under 1 atm of H₂, filtered and concentrated. The residue was dissolved in 50 mL of CH₂Cl₂, then treated with NEt₃ (1.00 mL, 7.17 mmol) and PivCl (0.500 mL, 4.05 mmol). The reaction mixture was stirred for 1 h, diluted with CH₂Cl₂, washed with 10% HCl and saturated NaHCO₃, dried (MgSO₄), filtered, and concentrated. Chromatography on SiO₂ (EtOAc/hexanes, 3:7) gave 513 mg (72%) of the desired oily pivaloyl amide: *R*_f 0.24 (EtOAc/hexanes, 1:1); ¹H NMR δ 7.59 (d, 2 H, *J* = 8.2, 7.2 Hz), 7.40 (t, 2 H, *J* = 7.1 Hz), 7.32 (d, 1 H, *J* = 7.1 Hz), 7.24 (s, 1 H), 6.49 (br, 1 H), 4.61 (d, 2 H, *J* = 5.1 Hz), 1.26 (s, 9 H); ¹³C NMR δ 178.6, 160.4, 151.9, 128.9, 128.6, 127.7, 124.2, 121.7, 38.8, 37.2, 27.6.

A solution of this pivaloyl amide (96 mg, 0.38 mmol) in 2 mL of THF was treated at -78 °C with a 1.6 M solution of BuLi in hexane (0.250 mL, 0.400 mmol), Boc₂O (166 mg, 0.806 mmol), and DMAP (5.0 mg, 0.041 mmol). The reaction mixture was stirred overnight at room temperature, diluted with CH₂Cl₂, washed with 10% HCl and 2 N NaOH, dried (MgSO₄), filtered, and concentrated. Chromatography on SiO₂ (EtOAc/hexanes, 1:9) gave 36 mg (38%) of recovered starting material, and 58 mg (43%) of the desired oily imide **13**: *R*_f 0.60 (EtOAc/hexanes, 3:7); IR 1747, 1741, 1688 cm⁻¹; ¹H NMR δ 7.58 (d, 1 H, *J* = 8.5 Hz), 7.57 (d, 1 H, *J* = 7.2 Hz); 7.39 (t, 2 H, *J* = 7.2 Hz); 7.31 (d, 1 H, *J* = 5.2 Hz), 7.25 (s, 1 H), 4.90 (s, 2 H), 1.46 (s, 9 H), 1.38 (s, 9 H); ¹³C NMR δ 184.9, 160.2, 153.1, 151.3, 128.9, 128.4, 127.9, 124.1, 122.1, 83.4, 44.1, 43.5, 28.1, 27.9; MS (EI) *m/z* (rel. intensity) 358 (M⁺, 15), 287 (10), 258 (65), 201 (77), 173 (45), 153 (30), 136 (22), 107 (26); HRMS (EI) *m/z* calculated for C₂₀H₂₆N₂O₄, 358.1893, found 358.1896.

[3,3-Dimethyl-2-oxo-1-(5-phenyl-oxazol-2-yl)-butyl]-carbamic acid *tert*-butyl ester (14). A solution of *i*-Pr₂NH (0.100 mL, 0.715 mmol) in 1 mL of THF was treated with a 1.6 M solution of BuLi in hexane (0.500 mL, 0.800 mmol) and cooled to -78 °C. A solution of **13** (58 mg, 0.162 mmol) in 1 mL of THF was added and the mixture was stirred for 30 min, quenched with saturated NH₄Cl, and extracted into EtOAc. The EtOAc layer was washed with 10% HCl and saturated NaHCO₃, dried (Na₂SO₄), filtered, and concentrated. Chromatography on SiO₂

(EtOAc/hexanes, 1:9 to 3:7) provided the rearranged product as an oil (51.5 mg; 89%): R_f 0.60 (EtOAc/hexanes, 3:7); IR 1713 cm^{-1} ; 7.62 (d, 2 H, $J = 7.2$ Hz), 7.42 (t, 2 H, $J = 7.0$ Hz), 7.36 (d, 1 H, $J = 7.1$ Hz), 7.30 (s, 1 H), 6.06 (d, 1 H, $J = 8.4$ Hz), 5.85 (d, 1 H, $J = 7.7$ Hz), 1.45 (s, 9 H), 1.20 (s, 9 H); ^{13}C NMR δ 207.7, 158.5, 154.7, 152.2, 129.0, 128.9, 127.4, 124.4, 122.4, 80.6, 52.7, 44.3, 28.3, 26.4; MS (EI) m/z (rel. intensity) 358 (M^+ , 1), 285 (5), 273 (8), 217 (24), 200 (22), 173 (100); HRMS (EI) m/z calculated for $\text{C}_{20}\text{H}_{26}\text{N}_2\text{O}_4$ 358.1893, found 358.1902.

***N*-(5'-*tert*-Butyl-5-phenyl-[2,4']bioxazolyl-2'-ylmethyl)-benzamide**

(15). A solution of **14** (73 mg, 0.20 mmol) in 3 mL of ether pre-saturated with HCl was stirred for 1 h and concentrated to dryness. In a separate flask, *N*-benzoyl-glycine² (50 mg, 0.28 mmol) was dissolved in 2 mL of DMF and treated with *N*-methylmorpholine (0.100 mL, 0.91 mmol). To this solution was added at -30 °C, isobutylchloroformate (0.040 mL, 0.30 mmol). The mixture was stirred for 10 min, treated with a solution of the deprotected amine in 1 mL of DMF, stirred at -20 °C for 2 h, diluted with EtOAc, washed with 10% HCl and saturated NaHCO_3 , dried (MgSO_4), filtered and concentrated. Chromatography on SiO_2 (EtOAc/hexanes, 1:1) gave 59 mg (70%) of the desired Bz-Gly adduct as an oil: R_f 0.06 (EtOAc/hexanes, 1:1); ^1H NMR δ 7.89 (d, 1 H, $J = 7.9$ Hz), 7.82 (d, 2 H, $J = 7.2$ Hz), 7.57-7.54 (m, 2 H), 7.47-7.28 (m, 7 H), 7.25 (s, 1 H), 6.37 (d, 1 H, $J = 7.6$ Hz), 4.29 (d, 2 H, $J = 5.1$ Hz), 1.19 (s, 9 H).

A solution of the Bz-Gly adduct (59 mg, 0.14 mmol) in 1 mL of toluene was treated with *p*-TsOH (10 mg, 0.053 mmol) and stirred for 2 d at 90 °C. The reaction mixture was cooled, diluted with EtOAc, washed with 10% HCl and saturated NaHCO_3 , dried (MgSO_4), filtered, and concentrated. Chromatography on SiO_2 (EtOAc/hexanes, 1:4 to 1:1) gave 32 mg (57%) of bisoxazole **15** as an oil: R_f 0.25 (EtOAc/hexanes, 1:1); IR 1651 cm^{-1} ; ^1H NMR δ 7.84-7.81 (m, 3 H), 7.62 (2 d, 2 H, $J = 8.4, 7.1$ Hz), 7.44-7.32 (m, 7 H), 4.80 (d, 2 H, $J = 5.4$ Hz), 1.50 (s, 9 H); ^{13}C NMR δ 167.7, 160.9, 158.7, 155.4, 151.6, 133.6, 131.8, 129.1, 128.7, 128.6, 127.8, 127.4, 124.4, 123.4, 123.3, 37.2, 33.2, 28.6; MS (EI) m/z (rel. intensity) 401 (M^+ , 80), 296 (100), 105 (95), 77 (44); HRMS (EI) calculated for $\text{C}_{24}\text{H}_{23}\text{N}_3\text{O}_3$, 401.1739, found 401.1741.

² Glase, S. A.; Akunne, H. G.; Georgic, L. M.; Heffner, T. G.; MacKenzie, R. G. *J. Med. Chem.* **1997**, *40*, 1771-1772.

[1-(5'-tert-Butyl-5-phenyl-[2,4']bioxazolyl-2'-yl)-2-oxo-2-phenylethyl]-carbamic acid tert-butyl ester (16). A solution of bisoxazole **15** (32 mg, 0.080 mmol) in 1 mL of THF was treated with DMAP (10 mg, 0.089 mmol) and Boc₂O (35 mg, 0.16 mmol). The reaction mixture was stirred for 19 h, diluted with EtOAc, washed with 10% HCl and saturated NaHCO₃, dried (MgSO₄), filtered and concentrated. Chromatography on SiO₂ (EtOAc/hexanes, 1:19 to 1:9) gave 37 mg (92%) of the desired imide as an oil: *R_f* 0.64 (EtOAc/hexanes, 1:1); ¹H NMR δ 7.76-7.71 (m, 4 H), 7.55-7.30 (m, 7 H), 5.20 (s, 2 H), 1.52 (s, 9 H), 1.22 (s, 9 H); ¹³C NMR δ 173.0, 160.5, 157.3, 155.7, 152.9, 151.3, 137.4, 131.6, 129.1, 128.6, 128.3, 128.1, 124.5, 123.8, 123.3, 84.0, 42.3, 33.2, 28.6, 27.6.

A solution of *i*-Pr₂NH (0.050 mL, 0.36 mmol) in 1 mL of THF was treated with a 1.6 M solution of BuLi in hexane (0.200 mL, 0.32 mmol) and cooled to -78 °C. A solution of the imide (35 mg, 0.070 mmol) in 1 mL of THF was added and the reaction mixture was stirred for 30 min, diluted with EtOAc, washed with 10% HCl and saturated NaHCO₃, dried (Na₂SO₄), filtered and concentrated. Chromatography on SiO₂ (EtOAc/hexanes, 1:9 to 3:7) gave 30 mg (86%) of oily **16**: *R_f* 0.64 (EtOAc/hexanes, 1:1); IR 1716, 1697 cm⁻¹; ¹H NMR δ 8.17 (d, 2 H, *J* = 7.5 Hz), 7.70 (d, 2 H, *J* = 7.3 Hz), 7.63 (d, 1 H, *J* = 7.3 Hz), 7.55-7.30 (m, 6 H), 6.58 (d, 1 H, *J* = 8.2 Hz), 6.18 (d, 1 H, *J* = 8.1 Hz), 1.50 (s, 9 H), 1.43 (s, 9 H); ¹³C NMR δ 191.8, 161.2, 156.3, 155.2, 151.7, 134.5, 134.1, 129.5, 129.1, 129.0, 128.8, 127.9, 124.5, 124.1, 123.3, 80.9, 54.3, 33.3, 28.6, 28.5; MS (EI) *m/z* (rel. intensity) 501 (M⁺, 5), 428 (5), 401 (6), 340 (6), 323 (25), 296 (60), 105 (70); HRMS (EI) *m/z* calculated for C₂₉H₃₁N₃O₅ 501.2264, found 501.2256.

(5'-tert-Butyl-5,5''-diphenyl-[2,4';2',4'']teroxazol-2''-ylmethyl)-carbamic acid benzyl ester (17). A solution of **16** (30 mg, 0.060 mmol) in 1 mL of ether pre-saturated with HCl was stirred for 30 min and concentrated to dryness. In a separate flask, a solution of Cbz-Gly¹ (50 mg, 0.24 mmol) and *i*-Pr₂NEt (0.200 mL, 1.15 mmol) in 1 mL of CH₂Cl₂ was treated at -20 °C with isobutylchloroformate (0.030 mL, 0.24 mmol) and stirred for 20 min. This reaction mixture was treated with a solution of the deprotected amine in 1 mL of CH₂Cl₂, stirred for 2 h, diluted with EtOAc and washed with 10% HCl and saturated NaHCO₃, dried (Na₂SO₄), filtered and concentrated. Chromatography on SiO₂ (EtOAc/hexanes, 1:4) gave 22.3 mg (63%) of the oily Cbz-glycine adduct: ¹H NMR δ 8.11 (d, 2 H, *J* = 7.4 Hz), 7.72 (t, 1 H, *J* = 7.1 Hz), 7.67-7.60 (m, 3 H), 7.55-7.25 (m, 10 H), 7.23 (s, 1 H), 6.82 (d, 1

H, $J = 7.6$ Hz), 5.64 (t, 1 H, $J = 5.2$ Hz), 5.15 (s, 2 H), 4.09 (d, 2 H, $J = 5.3$ Hz), 1.40 (s, 9 H).

A solution of this ketoamide (19.5 mg, 0.033 mmol) in 1 mL of toluene was treated with *p*-TsOH (10 mg, 0.0051 mmol) and stirred at 65 °C for 18 h. The reaction mixture was diluted with EtOAc and washed with saturated NaHCO₃, dried (Na₂SO₄), filtered and concentrated. Chromatography on SiO₂ (EtOAc/hexanes, 1:1) provided 12.7 mg (67%) of **17**: R_f 0.25 (EtOAc/hexanes, 1:1); IR 1722, 1651, 1635 cm⁻¹; ¹H NMR δ 8.18 (d, 1 H, $J = 8.0$ Hz), 8.17 (d, 1 H, $J = 7.5$ Hz), 7.79 (2 d, 2 H, $J = 8.6, 7.2$ Hz), 7.53-7.36 (m, 12 H), 5.60 (br m, 1 H), 5.22 (s, 2 H), 4.71 (d, 2 H, $J = 5.7$ Hz), 1.56 (s, 9 H); ¹³C NMR δ 160.7, 160.1, 155.4, 153.0, 151.6, 136.3, 130.2, 129.1, 128.8, 128.7, 128.5, 128.4, 128.1, 127.8, 127.1, 124.8, 124.6, 124.2, 123.3, 67.5, 38.7, 33.5, 28.7; MS (EI) m/z (rel. intensity) 574 (M^+ , 100), 559 (11), 517 (16), 466 (10), 439 (50); HRMS (EI) m/z calculated for C₃₄H₃₀N₄O₅ 574.2216, found 574.2213.

3-[2-(Benzyloxycarbonylamino-methyl)-oxazol-5-yl]-indole-1-carboxylic acid ethyl ester (19). A solution of Cbz-Gly¹ (2.40 g, 11.5 mmol) and *N*-methylmorpholine (5.00 mL, 45.4 mmol) in 50 mL of DMF was treated at -30 °C with isobutylchloroformate (1.50 mL, 11.6 mmol), stirred for 25 min, and treated with α -aminoketone monoacetic acid salt **18**³ (2.69 g, 11.5 mmol) was added. The mixture mixture was stirred at -20 °C for 2 h, diluted with 200 mL of CH₂Cl₂ and washed with 10% HCl. The suspension was filtered and the filtrate was concentrated and filtered. The combined precipitates were dried by azeotropic distillation with toluene to give 2.77 g (66%) of the desired ketoamide as a solid: mp 213.1-214.9 °C; IR (KBr) 1708, 1662, 1634 cm⁻¹; ¹H NMR (DMSO-*d*₆) δ 12.05 (s, 1 H), 8.45 (d, 1 H, $J = 3.1$ Hz), 8.20-8.15 (m, 2 H), 7.59 (t, 1 H, $J = 5.9$ Hz), 7.51-7.48 (m, 1 H), 7.38-7.29 (m, 5 H), 7.26-7.18 (m, 2 H), 5.07 (s, 2 H), 4.52 (d, 2 H, $J = 5.5$ Hz), 3.75 (d, 2 H, $J = 6.2$ Hz); ¹³C NMR δ 190.6, 170.0, 157.2, 137.7, 137.1, 134.4, 129.0, 128.4 (d), 126.0, 123.5, 122.5, 121.8, 114.6, 112.8, 66.1, 46.3, 44.2; MS (EI) m/z (rel. intensity) 365 (M^+ , 4), 257 (4), 144 (100); HRMS (EI) m/z calculated for C₂₀H₁₉N₃O₄ 365.1376, found 365.1391.

A suspension of this ketoamide (283 mg, 0.775 mmol), PPh₃ (350 mg, 1.55 mmol), and NEt₃ (0.500 mL, 3.59 mmol) in 30 mL of CH₂Cl₂ was treated portionwise with Cl₃CCCl₃ (370 mg, 1.57 mmol) over a 30 min period and stirred

³ Prepared according to Miyake, F. Y.; Yakushijin, K.; Horne, D. A. *Org. Lett.*, **2000**, 2, 2121-2123, and triturated with EtOH to a colorless solid.

for 1 h. The black solution was washed with 10% HCl and 2 N NaOH, dried (Na_2SO_4), filtered and concentrated. The residue was dissolved in 10 mL of CH_2Cl_2 and treated with ClCO_2Et (0.120 mL, 1.26 mmol), DMAP (10 mg, 0.082 mmol), and NEt_3 (0.200 mL, 1.44 mmol). The reaction mixture was stirred for 30 min, diluted with CH_2Cl_2 , washed with 10% HCl and 2 N NaOH, dried (Na_2SO_4), filtered and concentrated. Chromatography on SiO_2 (EtOAc/hexanes, 1:4 to 1:1) gave 171 mg (53%) of indolyloxazole **19** as a solid: R_f 0.26 (EtOAc/hexanes, 1:1); mp 134.0-135.5 °C; IR (KBr) 1744, 1724 cm^{-1} ; ^1H NMR δ 8.24 (d, 1 H, $J = 8.1$ Hz), 7.88 (s, 1 H), 7.73 (d, 1 H, $J = 7.7$ Hz), 7.45-7.30 (m, 7 H), 7.29 (s, 1 H), 5.84 (br m, 1 H), 5.20 (s, 2 H), 4.62 (d, 2 H, $J = 5.7$ Hz), 4.53 (q, 2 H, $J = 7.1$ Hz), 1.51 (t, 3 H, $J = 7.1$ Hz); ^{13}C NMR δ 159.6, 156.4, 150.7, 146.6, 136.3, 135.6, 128.6, 128.2, 126.5, 125.5, 123.7, 122.4, 120.1, 115.6, 109.7, 67.3, 63.7, 38.6, 14.5; MS (EI) m/z (rel. intensity) 419 (M^+ , 30), 311 (40), 284 (100); HRMS (EI) m/z calculated for $\text{C}_{23}\text{H}_{21}\text{N}_3\text{O}_5$ 419.1481, found 419.1492.

3-(2-[[*tert*-Butoxycarbonyl-(2,2-diphenyl-propionyl)-amino]-methyl]-oxazol-5-yl-indole-1-carboxylic acid ethyl ester (20). A solution of **19** (340 mg, 0.690 mmol) in 5 mL of EtOH was treated with 10% Pd/C (73 mg, 0.069 mmol) and degassed by repeated vacuum/ H_2 exchange. The suspension was stirred vigorously for 4 h at room temperature under 1 atm of hydrogen, filtered and concentrated. A solution of the oily residue in 5 mL of DMF was treated with 2,2-diphenylpropionic acid (230 mg, 1.02 mmol), *i*-Pr₂NEt (0.250 mL, 1.44 mmol), and benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate ("PyBOP", 520 mg, 1.00 mmol). The mixture was stirred at room temperature for 18 h, diluted with EtOAc, washed with 10% HCl and 2 N NaOH, dried (Na_2SO_4), filtered and concentrated. Chromatography on SiO_2 (EtOAc/ CH_2Cl_2 , 1:9) provided 253 mg (74%) of the desired coupling product as colorless foam: R_f 0.18 (EtOAc/hexanes, 1:1); IR 1748, 1660 cm^{-1} ; ^1H NMR δ 8.30 (d, 1 H, $J = 8.2$ Hz), 7.94 (s, 1 H), 7.80-7.77 (m, 1 H), 7.5-7.3 (m, 13 H), 6.21 (t, 1 H, $J = 5.4$ Hz), 4.72 (d, 2 H, $J = 5.6$ Hz), 4.58 (q, 2 H, $J = 7.1$ Hz), 2.10 (s, 3 H), 1.55 (t, 3 H, $J = 7.1$ Hz); ^{13}C NMR δ 175.4, 150.7, 144.7, 135.6, 129.1, 128.6, 128.3, 128.2, 127.2, 126.5, 125.5, 123.8, 122.4, 122.3, 120.1, 115.6, 109.9, 63.8, 57.1, 37.4, 27.2, 14.5; MS (EI) m/z (rel. intensity) 493 (M^+ , 75), 284 (45), 269 (41), 181 (100); HRMS (EI) m/z calculated for $\text{C}_{30}\text{H}_{27}\text{N}_3\text{O}_4$ 493.2002, found 493.2014.

A solution of this coupling product (193 mg, 0.391 mmol) in 5 mL of THF was treated at -78 °C with a 1.6 M solution of BuLi in hexane (0.250 mL, 0.400

mmol), Boc₂O (170 mg, 0.787 mmol), and DMAP (44 mg, 0.39 mmol). The reaction mixture was stirred at room temperature for 18 h, diluted with EtOAc, washed with 10% HCl and water, dried (Na₂SO₄), filtered and concentrated. Chromatography on SiO₂ (EtOAc/hexanes, 1:9 to 1:1) gave 69 mg (36%) of recovered starting material and 97 mg (42%) of oily imide **20**: *R*_f 0.55 (EtOAc/hexanes, 1:1); IR 1744 cm⁻¹; ¹H NMR δ 8.29 (d, 1 H, *J* = 8.0 Hz), 7.95 (s, 1 H), 7.83 (d, 1 H, *J* = 7.5 Hz), 7.45-7.18 (m, 13 H), 5.15 (s, 2 H), 4.55 (q, 2 H, *J* = 7.1 Hz), 2.12 (s, 3 H), 1.50 (t, 3 H, *J* = 7.1 Hz), 1.08 (s, 9 H); ¹³C NMR δ 180.0, 159.3, 151.0, 150.7, 146.0, 144.3, 135.7, 128.7, 128.5, 128.2, 127.9, 126.6, 126.3, 125.5, 123.8, 122.8, 122.1, 120.3, 115.6, 110.1, 83.6, 63.7, 60.6, 43.8, 31.2, 27.4, 14.5; MS (EI) *m/z* (rel. intensity) 593 (M⁺, 3), 493 (35), 361 (22), 345 (15), 312 (24), 269 (47), 181 (100); HRMS (EI) *m/z* calculated for C₃₅H₃₅N₃O₆ 593.2526, found 593.2535.

3-[2-(1-*tert*-Butoxycarbonylamino-2-oxo-3,3-diphenyl-butyl)-oxazol-5-yl]-indole-1-carboxylic acid ethyl ester (21). A solution of *i*-Pr₂NH (0.200 mL, 1.43 mmol) in 1 mL of THF was treated with a 1.6 M solution of BuLi in hexane (0.600 mL, 0.960 mmol) and cooled to -78 °C. A solution of **20** (121 mg, 0.204 mmol) in 1 mL of THF was added and the reaction mixture was stirred for 30 min, quenched with saturated NH₄Cl and extracted into EtOAc. The EtOAc layer was washed with 10% HCl and saturated NaHCO₃, dried (Na₂SO₄), filtered and concentrated. Chromatography on SiO₂ (EtOAc/hexanes, 1:4) gave 94 mg (78%) of oily **21**: *R*_f 0.51 (EtOAc/hexanes, 1:1); IR 1743, 1714 cm⁻¹; ¹H NMR δ 8.29 (d, 1 H, *J* = 8.0 Hz), 7.75 (s, 1 H), 7.70 (d, 1 H, *J* = 7.6 Hz), 7.46-7.14 (m, 13 H), 6.05 (d, 1 H, *J* = 8.7 Hz), 5.95 (d, 1 H, *J* = 8.1 Hz), 4.59 (q, 2 H, *J* = 7.1 Hz), 2.10 (s, 3 H), 1.57 (t, 3 H, *J* = 7.1 Hz), 1.48 (s, 9 H); ¹³C NMR δ 204.1, 157.1, 154.7, 150.8, 146.7, 142.5, 142.3, 135.7, 128.9, 128.6, 128.5, 128.3, 127.2, 126.5, 125.6, 123.9, 123.0, 120.3, 115.7, 109.7, 80.8, 63.9, 61.7, 54.5, 28.4, 27.9, 26.3, 14.6; MS (EI) *m/z* (rel. intensity) 401 (M⁺, 80), 296 (100), 105 (95); HRMS (EI) *m/z* calculated for C₃₅H₃₅N₃O₆ 593.2526, found 593.2518.


3-[2'-(1-Benzylloxycarbonylamino-2-methyl-propyl)-5'-(1,1-diphenyl-ethyl)-[2,4']bioxazolyl-5-yl]-indole-1-carboxylic acid ethyl ester (22). A solution of **21** (137 mg, 0.231 mmol) in 2 mL of Et₂O pre-saturated with HCl gas was stirred for 2 h. The reaction mixture was concentrated and the residue kept


under vacuum overnight. A solution of Cbz-*L*-valine⁴ (90 mg, 0.359 mmol) in 1 mL of CH₂Cl₂ was treated with *i*-Pr₂NEt (0.150 mL, 1.36 mmol), and at –30 °C, isobutylchloroformate (0.045 mL, 0.347 mmol). The reaction mixture was stirred for 20 min. at –20 °C, and treated with a solution of the deprotected amine in 1 mL of CH₂Cl₂. The reaction mixture was slowly warmed to 0 °C over 4 h, diluted with EtOAc, washed with 10% HCl and 1 N NaOH, dried (Na₂SO₄), filtered and concentrated. Chromatography on SiO₂ (EtOAc/hexanes, 1:4) gave 119 mg (71%) of the valine adduct as an oily 1:1 mixture of diastereomers: *R*_f 0.15 (EtOAc/hexanes, 3:7); ¹H NMR δ 8.29 (d, 1 H, *J* = 8.1 Hz), 7.75 (s, 1 H), 7.68 (d, 1 H, *J* = 7.5 Hz), 7.5–7.1 (m, 19 H), 6.28, 6.27 (2 d, 1 H, *J* = 8.1, 7.8 Hz), 5.38, 5.32 (2 d, 1 H, *J* = 8.8, 10.9 Hz), 5.16–5.10 (m, 2 H), 4.62–4.55 (m, 2 H), 4.22–4.15 (m, 1 H), 2.25–2.05 (m, 1 H), 2.08–2.07 (m, 3 H), 1.59–1.54 (m, 3 H), 1.02–0.87 (m, 6 H).


A solution of this ketoamide (25 mg, 0.034 mmol) in 2 mL of toluene was stirred at 65 °C in the presence of 4 Å MS (200 mg) and TsOH (1.0 mg, 0.0051 mmol) for 4 d. The reaction mixture was diluted with EtOAc and washed with saturated NaHCO₃, dried (Na₂SO₄), filtered and concentrated. Chromatography on SiO₂ (EtOAc/hexanes, 1:4) gave 14 mg (58%) of the desired oily bisoxazole **22**⁵: *R*_f 0.20 (EtOAc/hexanes, 3:7); [α]_D –13 (c 0.93, CH₂Cl₂); IR 1740, 1643 cm^{–1}; ¹H NMR 8.25 (d, 1 H, *J* = 8.3 Hz), 7.62 (d, 1 H, *J* = 7.8 Hz), 7.59 (s, 1 H), 7.45–7.16 (m, 18 H), 5.66 (d, 1 H, *J* = 8.9 Hz), 5.16, 5.15 (AB, 2 H, *J* = 12.2 Hz), 4.91 (dd, 1 H, *J* = 8.8, 5.6 Hz), 4.57 (q, 2 H, *J* = 7.1 Hz), 2.3–2.1 (m, 1 H), 2.24 (s, 3 H), 1.53 (t, 3 H, *J* = 7.1 Hz), 0.95 (d, 6 H, *J* = 6.7 Hz); ¹³C NMR δ 162.2, 157.3, 156.1, 153.8, 150.7, 146.3, 144.7, 136.3, 135.5, 128.6, 128.2 (2C), 128.1, 127.8 (2C), 127.0, 126.5, 125.7, 125.4, 123.7, 123.4, 122.7, 120.2, 115.5, 109.6, 67.1, 63.7, 54.8, 49.8, 33.2, 28.7, 18.5, 18.1, 14.5; MS (EI) *m/z* (rel. intensity) 708 (M⁺, 70), 690 (8), 621 (10), 600 (35); HRMS (EI) *m/z* calculated for C₄₃H₄₀N₄O₆ 708.2948, found 708.2957.


⁴ Faessler, A.; Bold, G.; Capraro, H.-G.; Cozens, R.; Mestan, J. *J. Med. Chem.*, **1996**, 39, 3203–3216.

⁵ Mosher amide analysis with both (*R*)-MTPA and (*S*)-MTPA indicated >95:5 enantiomeric purity. For a procedure, see Dale, J. A.; Dull, D. L.; Mosher, H. S. *J. Org. Chem.*, **1969**, 34, 2543–2549.







Phenyl CH₂NHPiv Oxazole 300 MHz CDCl₃ rt

Phenyl Oxazole CH₂NHPiv 75 MHz CDCl₃ rt 12 sec delay 115 scans

27.554



37.229
38.82176.751
77.176
77.600121.736
124.169
127.696
128.580
128.940

151.897

160.421


178.644

ppm



Phenyl Oxazole Boc/Piv Chan Precursor 300 MHz CDCl₃ rt

ppm
7.59112
7.58681
7.56265
7.41267
7.38869
7.36299
7.34193
7.30209
7.29568
7.27053
7.24839



4.89704

1.45625
1.37805

Integral

1.9364
2.0570
0.9373
0.2404
1.0928

2.0000

8.5061
8.4288

ppm

1

2


3

4

5

6

7




Phenyl Oxazole Boc/Piv Chan Product 300 MHz CDCl₃ rt

1.77205
1.48191
1.44598
1.38037
1.26048
1.19520
1.11756

6.07276
6.04486
5.86724
5.84173

7.63345
7.60943
7.44688
7.42352
7.39800
7.36704
7.34324
7.31785
7.29967
7.27078



ppm


8.9406
8.8928


1.0000
0.8742


1.2440
1.0767
2.2135
2.1392


Integral


1
2
3
4
5
6
7
8


Phenyl Oxazole Boc/Piv Chan Product 75 MHz CDCl₃ rt 12 sec delay 3034 scans





Bisoxazole 300 MHz, CDCl₃, rt











Bisoxazole Cbz-Gly adduct 300 MHz, CDCl₃, rt, 6 sec delay



ppm


8.12477
8.10016
7.67147
7.66683
7.64278
7.62116
7.52362
7.49774
7.44651
7.42289
7.40349
7.35909
7.35583
7.33554
7.27024


5.14711


4.09622
4.07843


1.39811























Ph2Me Boc Amide (Chan precursor) 300 MHz, CDCl₃, rt